Akari Therapeutics Plc Sponsored ADR Stock

$0.97

1.20% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

US00972G1085

Symbol

AKTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Akari Therapeutics Plc Sponsored ADR Stock price

$0.97

-33.43 97.19% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.01 1.20%

ISIN

US00972G1085

Symbol

AKTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$11.76m
Enterprise Value	$7.58m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-16.75m
Free Cash Flow (TTM) Free Cash Flow	$-16.30m
Cash position	$2.25m
Short interest	0.23%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Akari Therapeutics Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Akari Therapeutics Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	11 11	- -
- Research and Development Expense	5.43 5.43	- -
EBITDA	-17 -17	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-17 -17	22% 22% -
Net Profit	-9.95 -9.95	- -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Akari Therapeutics Plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

11 days ago

Akari Therapeutics Announces Key Leadership Appointments

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Samir R.

Neutral

GlobeNewsWire

●

13 days ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product ...

Neutral

GlobeNewsWire

●

about one month ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -

More Akari Therapeutics Plc Sponsored ADR News

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	Samir Patel
Founded	2004
Website	www.akaritx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now